Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017636 (
glioblastoma
)
18,345
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A better understanding of the molecules implicated in the growth and survival of
glioblastoma
(
GBM
) cells and their response to temozolomide (TMZ), the standard-of-care chemotherapeutic agent, is necessary for the development of new therapies that would improve the outcome of current
GBM
treatments. In this study, we characterize the role of
pericentriolar material 1
(
PCM1
), a component of centriolar satellites surrounding centrosomes, in
GBM
cell proliferation and sensitivity to genotoxic agents such as TMZ. We show that
PCM1
is expressed around centrioles and ciliary basal bodies in patient
GBM
biopsies and derived cell lines and that its localization is dynamic throughout the cell cycle. To test whether
PCM1
mediates
GBM
cell proliferation and/or response to TMZ, we used CRISPR/Cas9 genome editing to generate primary
GBM
cell lines depleted of
PCM1
. These
PCM1
-depleted cells displayed reduced AZI1 satellite protein localization and significantly decreased proliferation, which was attributable to increased apoptotic cell death. Furthermore,
PCM1
-depleted lines were more sensitive to TMZ toxicity than control lines. The increase in TMZ sensitivity may be partly due to the reduced ability of
PCM1
-depleted cells to form primary cilia, as depletion of KIF3A also ablated
GBM
cells' ciliogenesis and increased their sensitivity to TMZ while preserving
PCM1
localization. In addition, the co-depletion of KIF3A and
PCM1
did not have any additive effect on TMZ sensitivity. Together, our data suggest that
PCM1
plays multiple roles in
GBM
pathogenesis and that associated pathways could be targeted to augment current or future anti-
GBM
therapies.
...
PMID:PCM1 Depletion Inhibits Glioblastoma Cell Ciliogenesis and Increases Cell Death and Sensitivity to Temozolomide. 2766 4